Clinical Guest Contributors

  1. What Sponsors Must Know About Digital Systems And AI Compliance 7/17/2025

    Consultant Jessica Cordes provides an update on proposed changes to GMP guidance that affect trial conduct, including documentation, computerized systems, and the use of AI.

  2. More Personalized, Precision Medicine Needed In Psychiatry Clinical Trials 7/16/2025

    Arrivo Bioventures' Joel Raskin, MD, and Greg Rigdon, Ph.D., discuss the importance of personalized and precision medicine in psychiatry clinical trials.

  3. 4 Centralized Comparator Sourcing Models To Fortify Supply Chains 7/15/2025

    A team at Novartis developed models to address the often-overlooked challenge of clinical trial comparator sourcing, a weak link that can derail trials.

  4. How To Avoid Hazards And Map A Safer, Smarter Path For AI, Part 2 7/15/2025

    The AI journey is full of hidden potholes, unexpected detours, and costly wrong turns. In part two of this series, Tanisha Patel and Vincent Puglia explore more considerations for integrating AI in clinical research.

  5. How To Avoid Hazards And Map A Safer, Smarter Path For AI, Part 1 7/15/2025

    Even with a clear destination with real rewards, the AI journey is full of hidden potholes, unexpected detours, and costly wrong turns. Tanisha Patel and Vincent Puglia explore several considerations when integrating AI in clinical research.

  6. From Protocol To People: Teva's Patient-First Clinical Trials Approach 7/14/2025

    Teva Pharmaceuticals' Head of Global Early Clinical Development Eran Harary, MD, shares how the company approaches drug development by getting patient input early and often.

  7. A Guide To Guidelines: How ICH And Others Help Us Conduct Better Trials 7/11/2025

    Guidelines abound in clinical research. So, how should sponsor companies and partners think about their role in ensuring compliance? Consultant Kamila Novak explores their importance.

  8. How An Australia-First Strategy Cut 63% From Our R&D Spend 7/10/2025

    Etira CEO Russell Hayward explains how conducting the company's early-stage trials in Australia has yielded big savings, shortened timelines, and produced FDA-ready data.

  9. Imunon Talks Passionate PIs, Endpoint Selection In Frontline Ovarian Cancer Trials 7/9/2025

    IMUNON CEO Stacy Lindborg, Ph.D. details the company’s successes in site selection, as well as trial design and execution, in Phase 2 and 3 trials for IMNN-001, a frontline treatment for ovarian cancer.

  10. Dear Pharma, The Creator Economy Is NOT Only For Beauty 7/7/2025

    Empactful Ventures CEO Denise N. Bronner has a message for pharma when it comes to influencer marketing: Adapt or become invisible. Here, she details the hazards of overlooking this powerful media channel.